Product Pipeline

We have multiple and diverse cancer immunotherapies in our pipeline. These are in clinical and preclinical development directed against a range of cancer targets that have been identified and validated by Immatics’ proprietary XPRESIDENT® technology platform.

 

 

Stage

Partners

  • Discovery
  • Lead
  • CMC
  • Phase I/II
IMA401
IMA402
IMA403
ACTengine®
Multiple programs
TCER®/DuoBody®
Multiple Programs
TCER®/BiTE®
Multiple Programs
Bispecific mAb
Multiple Programs
Immunotherapies
Multiple Programs
We use cookies to ensure that we give you the best experience on our website.